These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 35865376)

  • 1. Effects of BNP and Sacubitrilat/Valsartan on Atrial Functional Reserve and Arrhythmogenesis in Human Myocardium.
    Primessnig U; Deißler PM; Wakula P; Tran KL; Hohendanner F; von Lewinski D; Blaschke F; Knosalla C; Falk V; Pieske B; Grubitzsch H; Heinzel FR
    Front Cardiovasc Med; 2022; 9():859014. PubMed ID: 35865376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of sacubitril/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study.
    Nougué H; Pezel T; Picard F; Sadoune M; Arrigo M; Beauvais F; Launay JM; Cohen-Solal A; Vodovar N; Logeart D
    Eur J Heart Fail; 2019 May; 21(5):598-605. PubMed ID: 30520545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sacubitrilat reduces pro-arrhythmogenic sarcoplasmic reticulum Ca
    Eiringhaus J; Wünsche CM; Tirilomis P; Herting J; Bork N; Nikolaev VO; Hasenfuss G; Sossalla S; Fischer TH
    ESC Heart Fail; 2020 Oct; 7(5):2992-3002. PubMed ID: 32710603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early B-Type Natriuretic Peptide Change in HFrEF Patients Treated With Sacubitril/Valsartan: A Pooled Analysis of EVALUATE-HF and PROVE-HF.
    Myhre PL; Prescott MF; Murphy SP; Fang JC; Mitchell GF; Ward JH; Claggett B; Desai AS; Solomon SD; Januzzi JL
    JACC Heart Fail; 2022 Feb; 10(2):119-128. PubMed ID: 35115085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of sacubitril/valsartan on echo parameters in heart failure patients with reduced ejection fraction a prospective evaluation.
    Bayard G; Da Costa A; Pierrard R; Roméyer-Bouchard C; Guichard JB; Isaaz K
    Int J Cardiol Heart Vasc; 2019 Dec; 25():100418. PubMed ID: 31517034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF Trial.
    Myhre PL; Vaduganathan M; Claggett B; Packer M; Desai AS; Rouleau JL; Zile MR; Swedberg K; Lefkowitz M; Shi V; McMurray JJV; Solomon SD
    J Am Coll Cardiol; 2019 Mar; 73(11):1264-1272. PubMed ID: 30846338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Neprilysin Inhibition on Left Ventricular Remodeling in Patients With Asymptomatic Left Ventricular Systolic Dysfunction Late After Myocardial Infarction.
    Docherty KF; Campbell RT; Brooksbank KJM; Dreisbach JG; Forsyth P; Godeseth RL; Hopkins T; Jackson AM; Lee MMY; McConnachie A; Roditi G; Squire IB; Stanley B; Welsh P; Jhund PS; Petrie MC; McMurray JJV
    Circulation; 2021 Jul; 144(3):199-209. PubMed ID: 33983794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heart Failure With Reduced Ejection Fraction Is Characterized by Systemic NEP Downregulation.
    Pavo IJ; Pavo N; Kastner N; Traxler D; Lukovic D; Zlabinger K; Spannbauer A; Riesenhuber M; Lorant D; Bartko PE; Goliasch G; Hülsmann M; Winkler J; Gyöngyösi M
    JACC Basic Transl Sci; 2020 Jul; 5(7):715-726. PubMed ID: 32760858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sacubitril/valsartan: beyond natriuretic peptides.
    Singh JSS; Burrell LM; Cherif M; Squire IB; Clark AL; Lang CC
    Heart; 2017 Oct; 103(20):1569-1577. PubMed ID: 28689178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Angiotensin Receptor-Neprilysin Inhibitor in Arrhythmogenicity Following Left Atrial Appendage Closure in an Animal Model.
    Cheng WH; Lugtu IC; Chang SL; Liu SH; Chen SA; Lo LW
    Cardiovasc Drugs Ther; 2021 Aug; 35(4):759-768. PubMed ID: 33818689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial.
    Solomon SD; Rizkala AR; Gong J; Wang W; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Shi VC; Lefkowitz MP; McMurray JJV
    JACC Heart Fail; 2017 Jul; 5(7):471-482. PubMed ID: 28662936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erratum to: Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor.
    Ayalasomayajula S; Langenickel T; Pal P; Boggarapu S; Sunkara G
    Clin Pharmacokinet; 2018 Jan; 57(1):105-123. PubMed ID: 28527109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin Receptor Neprilysin Inhibitor Attenuates Myocardial Remodeling and Improves Infarct Perfusion in Experimental Heart Failure.
    Pfau D; Thorn SL; Zhang J; Mikush N; Renaud JM; Klein R; deKemp RA; Wu X; Hu X; Sinusas AJ; Young LH; Tirziu D
    Sci Rep; 2019 Apr; 9(1):5791. PubMed ID: 30962467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor.
    Ayalasomayajula S; Langenickel T; Pal P; Boggarapu S; Sunkara G
    Clin Pharmacokinet; 2017 Dec; 56(12):1461-1478. PubMed ID: 28417439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of angiotensin receptor neprilysin inhibitors on left atrial remodeling and prognosis in heart failure.
    Sun Y; Song S; Zhang Y; Mo W; Zhang X; Wang N; Xia Y; Tse G; Liu Y
    ESC Heart Fail; 2022 Feb; 9(1):667-675. PubMed ID: 34779134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of angiotensin receptor neprilysin inhibition on P-wave dispersion in heart failure with reduced ejection fraction.
    Okutucu S; Fatihoglu SG; Sabanoglu C; Bursa N; Sayin BY; Aksoy H; Oto A
    Herz; 2021 Apr; 46(Suppl 1):69-74. PubMed ID: 31796977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
    Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
    Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of angiotensin receptor neprilysin inhibitor, sacubitril/valsartan, on central nervous system amyloid-β concentrations and clearance in the cynomolgus monkey.
    Schoenfeld HA; West T; Verghese PB; Holubasch M; Shenoy N; Kagan D; Buono C; Zhou W; DeCristofaro M; Douville J; Goodrich GG; Mansfield K; Saravanan C; Cumin F; Webb RL; Bateman RJ
    Toxicol Appl Pharmacol; 2017 May; 323():53-65. PubMed ID: 28315356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin Receptor Neprilysin Inhibitor for Patients With Heart Failure and Reduced Ejection Fraction: Real-World Experience From Taiwan.
    Hsiao FC; Wang CL; Chang PC; Lu YY; Huang CY; Chu PH
    J Cardiovasc Pharmacol Ther; 2020 Mar; 25(2):152-157. PubMed ID: 31514513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Sacubitril/Valsartan Treatment on Left Ventricular Myocardial Torsion Mechanics in Patients with Heart Failure Reduced Ejection Fraction 2D Speckle Tracking Echocardiography.
    Elshafey WEH; Al Khoufi EA; Elmelegy EK
    J Cardiovasc Echogr; 2021; 31(2):59-67. PubMed ID: 34485030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.